Crohn’s disease is a chronic relapsing gastrointestinal condition. It is an inflammatory bowel disease that can affect any part of the gastrointestinal tract from mouth to anus, but most commonly affects the terminal ileum and colon. Individuals can present with a wide variety of symptoms, but diarrhoea, abdominal pain and weight loss are the most common. It is a rare condition, but GPs play an important role in recognising Crohn’s disease and supporting patients through their lifelong treatment.
Get full access to this article
View all access options for this article.
References
1.
Amzallag-BellengerEOudjitARuizAet al.(2012) Effectiveness of MR enterography for the assessment of small-bowel diseases beyond Crohn disease. Radiographics32(5): 1423–1444. DOI: 10.1148/rg.325115088.
2.
BernsteinCNLoftusEVNgSCet al.(2012) Hospitalisations and surgery in Crohn's disease. Gut61(4): 622–629. DOI: 10.1136/gutjnl-2011-301397.
3.
BorrenNConwayGGarberJet al.(2017) Crohn's disease patients with a concordant family history are diagnosed earlier and are at increased risk for complicated disease. Journal of Crohn’s & Colitis11: S431–S432.
4.
BurischJJessTMartinatoMet al.(2013) The burden of inflammatory bowel disease in Europe. Journal of Crohn’s & Colitis7(4): 322–337. DOI: 10.1016/j.crohns.2013.01.010.
5.
CalkinsBM (1989) A meta-analysis of the role of smoking in inflammatory bowel-disease. Digestive Diseases and Sciences34(12): 1841–1854. DOI: 10.1007/bf01536701.
6.
CanavanCAbramsKRMayberryJ (2006) Meta-analysis: Colorectal and small bowel cancer risk in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics23(8): 1097–1104. DOI: 10.1111/j.1365-2036.2006.02854.x.
7.
ClarkMColombelJFFeaganBCet al.(2007) American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology133(1): 312–339. DOI: 10.1053/j.gastro.2007.05.006.
8.
CummingsJKesavSTravisS (2008) Medical management of Crohn's disease. British Medical Journal336: 1062–1066.
9.
CuryDBMossAC (2014) Treatment of Crohn's disease in pregnant women: Drug and multidisciplinary approaches. World Journal of Gastroenterology20(27): 8790–8795. DOI: 10.3748/wjg.v20.i27.8790.
10.
EconomouMTrikalinosTALoizouKTet al.(2004) Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: A metaanalysis. American Journal of Gastroenterology99(12): 2393–2404. DOI: 10.1111/j.1572-0241.2004.40304.x.
11.
HalfvarsonJBodinLTyskCet al.(2003) Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology124(7): 1767–1773. DOI: 10.1016/s0016-5085(03)00385-8.
12.
HallT (2013) Paces for the MRCP, third edition, Edinburgh: Elsevier.
13.
HugotJPChamaillardMZoualiHet al.(2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature411: 599–603.
14.
JacksonCAClatworthyJRobinsonAet al.(2010) Factors associated with non-adherence to oral medication for inflammatory bowel disease: A systematic review. American Journal of Gastroenterology105(3): 525–539. DOI: 10.1038/ajg.2009.685.
LoftusEV (2004) Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology126(6): 1504–1517. DOI: 10.1053/j.gastro.2004.01.063.
17.
LoftusEVGuerinAYuAPet al.(2011) Increased risks of developing anxiety and depression in young patients with Crohn's disease. American Journal of Gastroenterology106(9): 1670–1677. DOI: 10.1038/ajg.2011.142.
18.
LoganRFA (1998) Inflammatory bowel disease incidence: Up, down or unchanged?Gut42(3): 309–311.
OguraYBonenDKInoharaNet al.(2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature411: 603–606.
21.
OrholmMBinderVSorensenTIAet al.(2000) Concordance of inflammatory bowel disease among Danish twins: Results of a nationwide study. Scandinavian Journal of Gastroenterology35(10): 1075–1081.
22.
PedersenNBortoliADuricovaDet al.(2013) The course of inflammatory bowel disease during pregnancy and postpartum: A prospective European ECCO-EpiCom Study of 209 pregnant women. Alimentary Pharmacology & Therapeutics38(5): 501–512. DOI: 10.1111/apt.12412.
23.
PhilpottDJSorbaraMTRobertsonSJet al.(2014) NOD proteins: Regulators of inflammation in health and disease. Nature Reviews Immunology14(1): 9–23. DOI: 10.1038/nri3565.
RubinGPHunginAPSKellyPJet al.(2000) Inflammatory bowel disease: Epidemiology and management in an English general practice population. Alimentary Pharmacology & Therapeutics14(12): 1553–1559. DOI: 10.1046/j.1365-2036.2000.00886.x.
28.
SawczenkoASandhuBK (2003) Presenting features of inflammatory bowel disease in Great Britain and Ireland. Archives of Disease in Childhood88(11): 995–1000. DOI: 10.1136/adc.88.11.995.
29.
ShinTOkadaH (2016) Infertility in men with inflammatory bowel disease. World Journal of Gastrointestinal Pharmacology and Therapeutics7(3): 361–369.
30.
ThomasGAORhodesJGreenJTet al.(2000) Role of smoking in inflammatory bowel disease: Implications for therapy. Postgraduate Medical Journal76(895): 273–279. DOI: 10.1136/pmj.76.895.273.
31.
Van der WoudeCJArdizzoneSBengtsonMBet al.(2015) The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. Journal of Crohn’s & Colitis9: 107–124.
32.
Van RheenenPFvan de VijverEFidlerV (2010) Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. British Medical Journal341: 11. DOI: 10.1136/bmj.c3369.
